<DOC>
	<DOCNO>NCT00654147</DOCNO>
	<brief_summary>A prospective , randomize , open-label pilot study ass virologic suppression immunologic recovery associate two-drug antiretroviral regimen Raltegravir protease inhibitor lopinavir/ritonavir ( LPV/r ) three drug regimen Raltegravir two nRTIs ( emtricitabine/tenofovir ) HIV-1 infected treatment-naïve subject . Immunology Substudy add determine kinetics recovery CD4 T cell subpopulation ( regulatory T cell [ T regs ] , TH-17 TH1 ) treatment initiation Raltegravir base regimen relationship functional CD8 T cell Raltegravir contain therapy lead decrease marker gut microbial translocation cellular soluble marker immune activation .</brief_summary>
	<brief_title>Raltegravir + Lopinavir/Ritonavir Emtricitabine/Tenofovir HIV Treatment Naive Subjects</brief_title>
	<detailed_description>A009 prospective , randomize , open-label pilot study ass virologic suppression immune recovery rate associate two-drug potent antiretroviral regimen raltegravir protease inhibitor lopinavir/ritonavir three-drug regimen raltegravir two nRTIs ( emtricitabine/tenofovir ) treatment-naïve subject . HIV-1-infected subject antiretroviral drug-naïve plasma HIV-1 RNA level ≥5000 copies/ml obtain within 30 day prior study entry randomize 1:1 Raltegravir 400 mg BID + LPV 400 mg/RTV 100 mg BID ( Arm A ) Raltegravir 400 mg BID + FTC 200 mg/TDF 300 mg QD ( Arm B ) . Subjects measurement HIV-1 RNA CD4+ CD8+ T-cell count pre-entry entry . The average measurement use establish baseline value . Following entry , subject plasma HIV-1 RNA sample draw day 2 , 4 , 8 week 2 , 4 , 8 , 16 , 24 , 32 , 40 48 virologic failure . CD38 expression CD4+/CD8+ cell CD38/HLA-DR activation antigen CD4+ CD8+ cell subsets T-cell percentage do entry , day 8 week 4 , 8 , 24 virologic failure advance flow cytometry .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<criteria>Documented HIV Infection Genotypic resistance without major resistance mutation within 30 day Antiretroviral drugnaïve Screening HIV1 RNA ≥5000 Women reproductive potential Negative pregnancy test within 48 hour Acute recent HIV1 infection Currently breast feed Use immunomodulators Evidence major resistance mutation HBsAg positive Acute hepatitis etiology clinically significant liver disease Current imprisonment involuntary incarceration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>antiretroviral therapy naive</keyword>
	<keyword>Integrase inhibitor</keyword>
	<keyword>HIV/AIDS</keyword>
	<keyword>treatment naïve</keyword>
</DOC>